Badar, T., Jamy, O., Lin, C., Patel, A., Wang, Y.-H., Shallis, R., … Litzow, M. (2025). Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study. In Blood (Vol. 146, pp. 874–874). American Society of Hematology. https://doi.org/10.1182/blood-2025-874

Badar, Talha, Omer Jamy, Chenyu Lin, Anand Patel, Yu-Hung Wang, Rory Shallis, Kendall Diebold, et al. “Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study.” In Blood, 146:874–874. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-874.

Badar T, Jamy O, Lin C, Patel A, Wang Y-H, Shallis R, et al. Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study. In: Blood. American Society of Hematology; 2025. p. 874–874.

Badar, Talha, et al. “Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 874–874. Crossref, doi:10.1182/blood-2025-874.

Badar T, Jamy O, Lin C, Patel A, Wang Y-H, Shallis R, Diebold K, Coltoff A, Goldberg A, Bewersdorf JP, Zabel K, Foucar C, Abaza Y, Guru Murthy GS, Palmisiano N, Duvall A, Kota V, Patel S, Zeidan A, Atallah E, Litzow M. Choice of hypomethylating agent for newly diagnosed TP53-mutant Acute Myeloid Leukemia: A command registry study. Blood. American Society of Hematology; 2025. p. 874–874.